why is retatrutide not working Working: Causes, Solutions and UK Alternatives – Bolt Pharmacy Retatrutide – Modern Longevity

The lipid improvements with Retatrutide emerge gradually over weeks and months

Retatrutide is not approved in the UK and should only be used as part of an authorised clinical trial

Key Takeaways Phase 2 retatrutide reduced mean systolic blood pressure by approximately 7-8 mmHg at top doses over 48 weeks Diastolic blood pressure dropped by approximately 2-4 mmHg Placebo arm BP changes were minimal, so the active-versus-placebo gap is real and meaningful The effect tracks with weight loss, suggesting most of the benefit is downstream of weight reduction rather than a direct vascular drug effect Patients on antihypertensive medications often need dose reductions as weight loss progresses to avoid excessive BP drops Direct answer Yes

This chronotropic effect, consistent with GLP-1 and glucagon receptor activation, averaged 5-10 beats per minute at peak and returned toward baseline by 48 weeks

In the SURMOUNT-1 clinical trial, patients taking the highest dose (15 mg) of tirzepatide lost about 21% of their body weight over 72 weeks